Top

Published in:

Open Access 01-04-2019 | Review article

Clinical epidemiology of infectious disease among patients with chronic kidney disease

Authors: Junichi Ishigami, Kunihiro Matsushita

Published in: Clinical and Experimental Nephrology | Issue 4/2019

Abstract

Infectious disease is recognized as an important complication among patients with end-stage renal disease, contributing to excess morbidity and health care costs. However, recent epidemiological studies have revealed that even mild to moderate stages of chronic kidney disease (CKD) substantially increase risk of infection. Regarding underlying mechanisms, evidence suggests various aspects of altered immune response in patients with CKD including impaired function of T cells, B cells and neutrophil. Multiple conditions surrounding CKD, such as older age, diabetes, and cardiovascular disease are important contributors in the increased susceptibility to infection in this population. In addition, several mechanisms impairing immune function have been hypothesized including accumulated uremic toxins, increased oxidative stress, endothelial dysfunction, low-grade inflammation, and mineral and bone disorders. In terms of prevention strategies, influenza and pneumococcal vaccines are most feasible and important. Nevertheless, the extent of vaccine utilization in CKD has not been well documented. In addition, antibody response to vaccination may be reduced in CKD patients, and thus a vaccine delivery strategy (e.g., dose and frequency) may need to be optimized among patients with CKD. Through this review, we demonstrate that infection is a major but underrecognized complication of CKD. As CKD is recognized as a serious public health issue, dedicated research is needed to better characterize the burden of infectious disease associated with CKD, understand the pathophysiology of infection in patients with CKD, and develop effective strategies to prevent infection and its sequela in this high risk population.

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72. https://doi.org/10.1016/S0140-6736(13)60687-X.CrossRefPubMed

United States Renal Data System. 2015 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015.

Barzilay JI, Fitzpatrick AL, Luchsinger J, Yasar S, Bernick C, Jenny NS, et al. Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis. 2008;52(2):216–26. https://doi.org/10.1053/j.ajkd.2007.12.044.CrossRefPubMedPubMedCentral

Daya NR, Voskertchian A, Schneider AL, Ballew S, McAdams DeMarco M, Coresh J, et al. Kidney function and fracture risk: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2016;67(2):218–26. https://doi.org/10.1053/j.ajkd.2015.06.020.CrossRefPubMed

Ishigami J, Grams ME, Naik RP, Coresh J, Matsushita K. Chronic kidney disease and risk for gastrointestinal bleeding in the community: the Atherosclerosis Risk in Communities (ARIC) Study. Clin J Am Soc Nephrol. 2016;11(10):1735–43. https://doi.org/10.2215/CJN.02170216.CrossRefPubMedPubMedCentral

Saran R, Robinson B, Abbott KC, Agodoa LY, Ayanian J, Bragg-Gresham J, et al US Renal Data System 2016 Annual Data Report. Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69(3S1):A7–8. https://doi.org/10.1053/j.ajkd.2016.12.004.CrossRefPubMedPubMedCentral

James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF, Hemmelgarn BR, et al. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008;168(21):2333–9. https://doi.org/10.1001/archinte.168.21.2333.CrossRefPubMed

James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 2009;54(1):24–32. https://doi.org/10.1053/j.ajkd.2009.04.005.CrossRefPubMed

Ishigami J, Grams ME, Chang AR, Carrero JJ, Coresh J, Matsushita K. CKD and risk for hospitalization with infection: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2016. https://doi.org/10.1053/j.ajkd.2016.09.018.CrossRefPubMedPubMedCentral

10.

Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ, et al. The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis. 2012;59(3):356–63. https://doi.org/10.1053/j.ajkd.2011.07.012.CrossRefPubMed

11.

McDonald HI, Thomas SL, Millett ER, Nitsch D. CKD and the risk of acute, community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records. Am J Kidney Dis. 2015;66(1):60–8. https://doi.org/10.1053/j.ajkd.2014.11.027.CrossRefPubMedPubMedCentral

12.

Xu H, Gasparini A, Ishigami J, Mzayen K, Su G, Barany P, et al. eGFR and the risk of community-acquired infections. Clin J Am Soc Nephrol. 2017;12(9):1399–408. https://doi.org/10.2215/CJN.00250117.CrossRefPubMedPubMedCentral

13.

Yates C, May K, Hale T, Allard B, Rowlings N, Freeman A, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32(10):1907–9. https://doi.org/10.2337/dc09-0295.CrossRefPubMedPubMedCentral

14.

Berns JS. Infection with antimicrobial-resistant microorganisms in dialysis patients. Semin Dial. 2003;16(1):30–7.CrossRefPubMed

15.

Ishigami J, Grams ME, Chang AR, Carrero JJ, Coresh J, Matsushita K. CKD and risk for hospitalization with infection: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2017;69(6):752–61. https://doi.org/10.1053/j.ajkd.2016.09.018.CrossRefPubMed

16.

Wang HE, Gamboa C, Warnock DG, Muntner P. Chronic kidney disease and risk of death from infection. Am J Nephrol. 2011;34(4):330–6. https://doi.org/10.1159/000330673.CrossRefPubMedPubMedCentral

17.

Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-specific deaths in non-dialysis-dependent CKD. J Am Soc Nephrol. 2015. https://doi.org/10.1681/ASN.2014101034.CrossRefPubMedPubMedCentral

18.

Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, et al. Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT). Am J Kidney Dis. 2015. https://doi.org/10.1053/j.ajkd.2015.02.324.CrossRefPubMedPubMedCentral

19.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. https://doi.org/10.1038/kisup.2012.73 CrossRef

20.

Litjens NH, van Druningen CJ, Betjes MG. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol. 2006;118(1):83–91. https://doi.org/10.1016/j.clim.2005.09.007.CrossRefPubMed

21.

Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol. 2002;13(1):204–12.PubMed

22.

Anding K, Gross P, Rost JM, Allgaier D, Jacobs E. The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant. 2003;18(10):2067–73. https://doi.org/10.1093/ndt/gfg330.CrossRefPubMed

23.

Gollapudi P, Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol. 2010;31(3):247–54. https://doi.org/10.1159/000276764.CrossRefPubMed

24.

Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2431–8. https://doi.org/10.1681/ASN.2004110929.CrossRefPubMed

25.

Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123(3):958–65. https://doi.org/10.1172/JCI64096.CrossRefPubMedPubMedCentral

26.

Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol. 2009;9(1):57–62. https://doi.org/10.1038/nri2471.CrossRefPubMed

27.

Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–65. https://doi.org/10.1136/thoraxjnl-2013-204282.CrossRefPubMed

28.

Cheikh Hassan HI, Tang M, Djurdjev O, Langsford D, Sood MM, Levin A. Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality. Kidney Int. 2016;90(4):897–904. https://doi.org/10.1016/j.kint.2016.07.013.CrossRefPubMed

29.

Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol. 2003;14(7):1863–70.CrossRefPubMed

30.

Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014;25(9):1897–907. https://doi.org/10.1681/ASN.2013101062.CrossRefPubMedPubMedCentral

31.

Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant. 2007;22(2):592–6. https://doi.org/10.1093/ndt/gfl584.CrossRefPubMed

32.

Kim HY, Yoo TH, Hwang Y, Lee GH, Kim B, Jang J, et al. Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD). Sci Rep. 2017;7(1):3057. https://doi.org/10.1038/s41598-017-03130-z.CrossRefPubMedPubMedCentral

33.

Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M, et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol. 2013;24(12):1981–94. https://doi.org/10.1681/ASN.2012030281.CrossRefPubMedPubMedCentral

34.

Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. 2010;25(11):3693–700. https://doi.org/10.1093/ndt/gfq251.CrossRefPubMed

35.

Banerjee T, Meyer TW, Shafi T, Hostetter TH, Melamed M, Zhu Y, et al. Free and total p-cresol sulfate levels and infectious hospitalizations in hemodialysis patients in CHOICE and HEMO. Medicine. 2017;96(6):e5799. https://doi.org/10.1097/MD.0000000000005799.CrossRefPubMedPubMedCentral

36.

Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84. https://doi.org/10.1056/NEJMoa1109400.CrossRefPubMedPubMedCentral

37.

Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63. https://doi.org/10.1038/nature09922.CrossRefPubMedPubMedCentral

38.

Zeisel SH, Warrier M. Trimethylamine N-Oxide, the microbiome, and heart and kidney disease. Ann Rev Nutr. 2017;37:157–81. https://doi.org/10.1146/annurev-nutr-071816-064732.CrossRef

39.

Sack MN, Fyhrquist FY, Saijonmaa OJ, Fuster V, Kovacic JC. Basic biology of oxidative stress and the cardiovascular system: Part 1 of a 3-Part series. J Am Coll Cardiol. 2017;70(2):196–211. https://doi.org/10.1016/j.jacc.2017.05.034.CrossRefPubMedPubMedCentral

40.

Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24(5):469–73.CrossRefPubMed

41.

Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial. 2009;22(6):636–43. https://doi.org/10.1111/j.1525-139X.2009.00659.x.CrossRefPubMed

42.

Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65(3):1009–16. https://doi.org/10.1111/j.1523-1755.2004.00465.x.CrossRefPubMed

43.

Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int. 2007;71(2):167–72. https://doi.org/10.1038/sj.ki.5002019.CrossRefPubMed

44.

Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun. 2015;57:1–13. https://doi.org/10.1016/j.jaut.2014.12.002.CrossRefPubMed

45.

Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, et al. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 2012;18(8):1217–23. https://doi.org/10.1038/nm.2843.CrossRefPubMed

46.

Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004;84(3):869–901. https://doi.org/10.1152/physrev.00035.2003.CrossRefPubMed

47.

Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004;43(2):244–53.CrossRefPubMed

48.

Salmon AH, Ferguson JK, Burford JL, Gevorgyan H, Nakano D, Harper SJ, et al. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J Am Soc Nephrol. 2012;23(8):1339–50. https://doi.org/10.1681/ASN.2012010017.CrossRefPubMedPubMedCentral

49.

Seliger SL, Salimi S, Pierre V, Giffuni J, Katzel L, Parsa A. Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults. BMC Nephrol. 2016;17(1):82. https://doi.org/10.1186/s12882-016-0303-x.CrossRefPubMedPubMedCentral

50.

Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, et al. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol. 2004;94(3):294–9. https://doi.org/10.1016/j.amjcard.2004.04.022.CrossRefPubMed

51.

Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120(6):502–9. https://doi.org/10.1161/CIRCULATIONAHA.109.864801.CrossRefPubMedPubMedCentral

52.

Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41(6):1212–8.CrossRefPubMed

53.

Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7(12):1938–46. https://doi.org/10.2215/CJN.03500412.CrossRefPubMedPubMedCentral

54.

Wang HE, Shapiro NI, Safford MM, Griffin R, Judd S, Rodgers JB, et al. High-sensitivity C-reactive protein and risk of sepsis. PloS One. 2013;8(7):e69232. https://doi.org/10.1371/journal.pone.0069232.CrossRefPubMedPubMedCentral

55.

Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G. Inflammatory and endothelial activation biomarkers and risk of sepsis: a nested case-control study. J Crit Care. 2013;28(5):549–55. https://doi.org/10.1016/j.jcrc.2012.11.002.CrossRefPubMed

56.

Yende S, Tuomanen EI, Wunderink R, Kanaya A, Newman AB, Harris T, et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med. 2005;172(11):1440–6. https://doi.org/10.1164/rccm.200506-888OC.CrossRefPubMedPubMedCentral

57.

Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006;70(2):371–6. https://doi.org/10.1038/sj.ki.5001550.CrossRefPubMed

58.

Bacchetta J, Salusky IB, Hewison M. Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? Pediatr Nephrol. 2013;28(4):577–82. https://doi.org/10.1007/s00467-012-2336-0.CrossRefPubMed

59.

Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol. 2016;27(1):227–37. https://doi.org/10.1681/ASN.2014101009.CrossRefPubMed

60.

Nowak KL, Bartz TM, Dalrymple L, de Boer IH, Kestenbaum B, Shlipak MG, et al. Fibroblast growth factor 23 and the risk of infection-related hospitalization in older adults. J Am Soc Nephrol. 2016. https://doi.org/10.1681/ASN.2016040401.CrossRefPubMedPubMedCentral

61.

Ishigami J, Jaar BG, Rebholz CM, Grams ME, Michos ED, Wolf M, et al. Biomarkers of mineral and bone metabolism and 20-year risk for hospitalization with infection: the ARIC study. J Clin Endocrinol Metab. 2017. https://doi.org/10.1210/jc.2017-01868.CrossRefPubMedPubMedCentral

62.

Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. https://doi.org/10.1136/bmj.i6583.CrossRefPubMedPubMedCentral

63.

European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe. https://ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-europe. Accessed 30 Jan 2018.

64.

World Health Organization. Influenza vaccine use. http://www.who.int/influenza/vaccines/use/en/. Accessed 30 Jan 2018.

65.

Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348(14):1322–32. https://doi.org/10.1056/NEJMoa025028.CrossRefPubMed

66.

Grijalva CG, Zhu Y, Williams DJ, Self WH, Ampofo K, Pavia AT, et al. Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination. JAMA. 2015;314(14):1488–97. https://doi.org/10.1001/jama.2015.12160.CrossRefPubMedPubMedCentral

67.

Hak E, Nordin J, Wei F, Mullooly J, Poblete S, Strikas R, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis. 2002;35(4):370–7. https://doi.org/10.1086/341403.CrossRefPubMed

68.

Gilbertson DT, Unruh M, McBean AM, Kausz AT, Snyder JJ, Collins AJ. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int. 2003;63(2):738–43. https://doi.org/10.1046/j.1523-1755.2003.00787.x.CrossRefPubMed

69.

McGrath LJ, Kshirsagar AV, Cole SR, Wang L, Weber DJ, Sturmer T, et al. Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med. 2012;172(7):548–54. https://doi.org/10.1001/archinternmed.2011.2238.CrossRefPubMedPubMedCentral

70.

Wang IK, Lin CL, Lin PC, Liang CC, Liu YL, Chang CT, et al. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PloS One. 2013;8(3):e58317. https://doi.org/10.1371/journal.pone.0058317.CrossRefPubMedPubMedCentral

71.

Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, et al. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Vaccine. 2012;30(33):5009–18. https://doi.org/10.1016/j.vaccine.2012.05.016.CrossRefPubMed

72.

Lertdumrongluk P, Changsirikulchai S, Limkunakul C, Prachukthum P, Punpiput P, Buppanharun R, et al. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients. Vaccine. 2012;30(6):1108–14. https://doi.org/10.1016/j.vaccine.2011.12.023.CrossRefPubMed

73.

Birdwell KA, Ikizler MR, Sannella EC, Wang L, Byrne DW, Ikizler TA, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis. 2009;54(1):112–21. https://doi.org/10.1053/j.ajkd.2008.09.023.CrossRefPubMedPubMedCentral

74.

Crespo M, Collado S, Mir M, Cao H, Barbosa F, Serra C, et al. Efficacy of influenza A H1N1/2009 vaccine in hemodialysis and kidney transplant patients. Clin J Am Soc Nephrol. 2011;6(9):2208–14. https://doi.org/10.2215/CJN.02160311.CrossRefPubMedPubMedCentral

75.

Scharpe J, Peetermans WE, Vanwalleghem J, Maes B, Bammens B, Claes K, et al. Immunogenicity of a standard trivalent influenza vaccine in patients on long-term hemodialysis: an open-label trial. Am J Kidney Dis. 2009;54(1):77–85. https://doi.org/10.1053/j.ajkd.2008.11.032.CrossRefPubMed

76.

Ortbals DW, Marks ES, Liebhaber H. Influenza immunization in patients with chronic renal disease. JAMA. 1978;239(24):2562–5.CrossRefPubMed

77.

Izurieta HS, Thadani N, Shay DK, Lu Y, Maurer A, Foppa IM, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15(3):293–300. https://doi.org/10.1016/S1473-3099(14)71087-4.CrossRefPubMedPubMedCentral

78.

DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–45. https://doi.org/10.1056/NEJMoa1315727.CrossRefPubMed

79.

Noh JY, Song JY, Choi WS, Lee J, Seo YB, Kwon YJ, et al. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines. Hum Vaccin Immunother. 2016;12(11):2902–8. https://doi.org/10.1080/21645515.2016.1191717.CrossRefPubMedPubMedCentral

80.

Broeders NE, Hombrouck A, Lemy A, Wissing KM, Racape J, Gastaldello K, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol. 2011;6(11):2573–8. https://doi.org/10.2215/CJN.04670511.CrossRefPubMedPubMedCentral

81.

Chang YT, Wang JR, Lin MT, Wu CJ, Tsai MS, Wen-Chi CL, et al. Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients—an 18-week, open-label trial. Sci Rep. 2016;6:20725. https://doi.org/10.1038/srep20725.CrossRefPubMedPubMedCentral

82.

Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. https://doi.org/10.1056/NEJMoa1408544.CrossRefPubMed

83.

Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. The Cochrane Database Syst Rev. 2013;1:CD000422. https://doi.org/10.1002/14651858.CD000422.pub3.CrossRef

84.

Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis. 2012;60(6):959–65. https://doi.org/10.1053/j.ajkd.2012.04.018.CrossRefPubMed

85.

Gilbertson DT, Guo H, Arneson TJ, Collins AJ. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrol Dial Transpl. 2011;26(9):2934–9. https://doi.org/10.1093/ndt/gfq853.CrossRef

86.

Linnemann CC Jr, First MR, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med. 1986;146(8):1554–6.CrossRefPubMed

87.

Fuchshuber A, Kuhnemund O, Keuth B, Lutticken R, Michalk D, Querfeld U. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transpl. 1996;11(3):468–73.CrossRef

88.

Nikoskelainen J, Koskela M, Forsstrom J, Kasanen A, Leinonen M. Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure. Kidney Int. 1985;28(4):672–7.CrossRefPubMed

89.

Mitra S, Stein GE, Bhupalam S, Havlichek DH. Immunogenicity of 13-valent conjugate pneumococcal vaccine in patients 50 years and older with end-stage renal disease and on dialysis. Clin Vaccine Immunol. 2016;23(11):884–7. https://doi.org/10.1128/CVI.00153-16.CrossRefPubMedPubMedCentral

90.

Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187(10):1639–45. https://doi.org/10.1086/374784.CrossRefPubMed

91.

Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients–three year follow-up of a randomized trial. Am J Transplant. 2007;7(3):633–8. https://doi.org/10.1111/j.1600-6143.2007.01668.x.CrossRefPubMed

92.

Tobudic S, Plunger V, Sunder-Plassmann G, Riegersperger M, Burgmann H. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PloS One. 2012;7(9):e46133. https://doi.org/10.1371/journal.pone.0046133.CrossRefPubMedPubMedCentral

93.

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305. https://doi.org/10.1056/NEJMoa041031.CrossRefPubMed

94.

Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–208. https://doi.org/10.1056/NEJMoa1306801.CrossRefPubMedPubMedCentral

95.

World Health Organization. Department of Communicable Disease, Surveillance and Response. Prevention ofhospital-acquiredinfections. http://apps.who.int/medicinedocs/documents/s16355e/s16355e.pdf. Accessed 05 May 2018.

96.

Flodgren G, Conterno LO, Mayhew A, Omar O, Pereira CR, Shepperd S. Interventions to improve professional adherence to guidelines for prevention of device-related infections. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD006559.pub2.CrossRefPubMed

97.

Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. J Am Med Assoc. 2005;293(10):1223–38. https://doi.org/10.1001/jama.293.10.1223.CrossRef

98.

Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm. 2013;70(3):195–283. https://doi.org/10.2146/ajhp120568.CrossRefPubMed

99.

American Dental Association. Antibiotic Prophylaxis Prior to Dental Procedures. Available: https://www.ada.org/en/member-center/oral-health-topics/antibiotic-prophylaxis. Accessed 05 May 2018.

100.

Calfee DP. Multidrug-resistant organisms in dialysis patients. Semin Dial. 2013;26(4):447–56. https://doi.org/10.1111/sdi.12094.CrossRefPubMed

Title: Clinical epidemiology of infectious disease among patients with chronic kidney disease
Authors: Junichi Ishigami
Kunihiro Matsushita
Publication date: 01-04-2019
Publisher: Springer Singapore
Published in: Clinical and Experimental Nephrology / Issue 4/2019
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-018-1641-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats

Chronological renal resistive index increases related to atherosclerotic factors, and effect of renin-angiotensin system inhibitors

JAK2/STAT3/BMP-2 axis and NF-κB pathway are involved in erythropoietin-induced calcification in rat vascular smooth muscle cells

Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review

Survey of thrombotic microangiopathy within 1 week after kidney transplantation between 2010 and 2015 in Japan

Interleukin-33/ST2 signaling contributes to the severity of hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage